We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$121M
Cap. Flow %
-3.08%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Financials 0.15%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCC
101
CCC Intelligent Solutions
CCC
$4.19B
$556K 0.01%
+50,000
New +$569K
META icon
102
Meta Platforms (Facebook)
META
$1.52T
$555K 0.01%
+1,100
New +$535K
ADBE icon
103
Adobe
ADBE
$108B
$500K 0.01%
900
-2,200
-71% -$1.07M
INTA icon
104
Intapp
INTA
$3.16B
$477K 0.01%
13,000
-16,500
-56% -$561K
TSLA icon
105
Tesla
TSLA
$1.34T
$396K 0.01%
2,000
– –
RELY icon
106
Remitly
RELY
$5.39B
$303K 0.01%
+25,000
New +$388K
CYCN icon
107
Cyclerion Therapeutics
CYCN
$18.3M
$271K 0.01%
117,643
-21,312
-15% -$60.6K
GOSS icon
108
CALL
Gossamer Bio
GOSS
$83.3M
$186K ﹤0.01%
207,000
– –
CRBU icon
109
Caribou Biosciences
CRBU
$160M
$173K ﹤0.01%
105,347
– –
DELL icon
110
Dell
DELL
$320B
$138K ﹤0.01%
+1,000
New +$134K
DLO icon
111
dLocal
DLO
$4.34B
$84.8K ﹤0.01%
10,482
-19,518
-65% -$229K
PFTAW
112
DELISTED
Perception Capital Corp. III Warrant
PFTAW
$3.55K ﹤0.01%
+126,666
New +$4.57K
AAPL icon
113
Apple
AAPL
$4.46T
– –
-10,000
Closed -$1.71M
ADAG
114
Adagene
ADAG
$246M
– –
-1,020,000
Closed -$2.86M
AMD icon
115
Advanced Micro Devices
AMD
$789B
– –
-4,500
Closed -$812K
APGE icon
116
Apogee Therapeutics
APGE
$10.2B
– –
-152,500
Closed -$10.1M
ATXS
117
DELISTED
Astria Therapeutics
ATXS
– –
-884,214
Closed -$12.4M
AXSM icon
118
Axsome Therapeutics
AXSM
$11.2B
– –
-76,837
Closed -$6.13M
CLDX icon
119
Celldex Therapeutics
CLDX
$3.35B
– –
-253,000
Closed -$10.6M
CWAN
120
DELISTED
Clearwater Analytics
CWAN
– –
-25,000
Closed -$442K
FOLD
121
DELISTED
Amicus Therapeutics
FOLD
– –
-1,011,776
Closed -$11.9M
GERN icon
122
Geron
GERN
$982M
– –
-1,281,194
Closed -$4.23M
GPCR icon
123
Structure Therapeutics
GPCR
$3.89B
– –
-151,780
Closed -$6.51M
HIPO icon
124
Hippo Holdings
HIPO
$869M
– –
-24,000
Closed -$438K
INKT icon
125
MiNK Therapeutics
INKT
$54.8M
– –
-192
Closed -$1.74K
2 3 4
5
6

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group withdrew a net $121M in Q2 2024, closing 20 positions and reducing 29 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $29.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Artal Group opened a new position in Cullinan Oncology worth $18.5M.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.